A1 Proceedings of 2016 China Cancer Immunotherapy Workshop, Beijing, China
Bin Xue, Jiaqi Xu, Wenru Song, Zhimin Yang, Ke Liu, Zihai Li
A2 Set the stage: fundamental immunology in forty minutes
Zihai Li
A3 What have we learnt from the anti-PD-1/PD-L1 therapy of advanced human cancer?
Lieping Chen
A4 Immune checkpoint inhibitors in lung cancer
Edward B. Garon
A5 Mechanisms of response and resistance to checkpoint inhibitors in melanoma
Siwen Hu-Lieskovan
A6 Checkpoint inhibitor immunotherapy in lymphoid malignancies
Wei Ding
A7 Translational research to improve the efficacy of immunotherapy in genitourinary malignancies
Chong-Xian Pan
A8 Immune checkpoint inhibitors in gastrointestinal malignancies
Weijing Sun
A9 What’s next beyond PD-1/PDL1?
Yong-Jun Liu
A10 Cancer vaccines: new insights into the oldest immunotherapy strategy
Lei Zheng
A11 Bispecific antibodies for cancer immunotherapy
Delong Liu
A12 Updates on CAR-T immunotherapy
Michel Sadelain
A13 Adoptive T cell therapy: personalizing cancer treatment
Cassian Yee
A14 Immune targets and neoantigens for cancer immunotherapy
Rongfu Wang
A15 Phase I/IIa trial of chimeric antigen receptor modified T cells against CD133 in patients with advanced and metastatic solid tumors
Meixia Chen, Yao Wang, Zhiqiang Wu, Hanren Dai, Can Luo, Yang Liu, Chuan Tong, Yelei Guo, Qingming Yang, Weidong Han
A16 Cancer immunotherapy biomarkers: progress and issues
Lisa H. Butterfield
A17 Shaping of immunotherapy response by cancer genomes
Timothy A. Chan
A18 Unique development consideration for cancer immunotherapy
Wenru Song
A19 Immunotherapy combination
Ruirong Yuan
A20 Immunotherapy combination with radiotherapy
Bo Lu
A21 Cancer immunotherapy: past, present and future
Ke Liu
A22 Breakthrough therapy designation drug development and approval
Max Ning
A23 Current European regulation of innovative oncology medicines: opportunities for immunotherapy
Harald Enzmann, Heinz Zwierzina